Scrutinizing Primary Endpoints in ALS Clinical Trials: ALSFRS-R, Survival or a Composite?
During this webinar, Leonard van den Berg, MD, PhD (Chairman TRICALS | UMC Utrecht, NL) and Ruben van Eijk MD, PhD (Lead Statistician TRICALS | UMC Utrecht, NL) will discuss Primary endpoints in ALS clinical trials, differences in regulatory requirement of the EMA and FDA and statistical considerations.
They touched upon:
- Primary endpoints in ALS clinical trials
- Regulatory requirements: differences between EMA and FDA
- Statistical considerations for ALSFRS-R, survival and composites
Followed by a Q&A session.
Speakers: Prof. Leonard van den Berg, MD, PhD & Dr. Ruben van Eijk, MD, PhD
Related webinars
Webinar – Improving ALS Trial Delivery Through Insights from Patient and Industry Experience
On January 19, at 16.30 CET, we will present the webinar: Improving ALS Trial Delivery Through Insights from Patient and Industry ExperienceWhat You’ll LearnPatient- and Industry-Informed Insights Top patient-experience pitfalls obs...
Webinar – Boosting patient enrolment and retention in clinical trials: Expert Insights & Tips
On June 30, at 16.00 CEST, we will present the webinar: Boosting patient enrolment and retention in clinical trials: Expert Insights & TipsJoin us for an interactive discussion with experts who will draw upon recent cardiology and neurolog...
Webinar – The role of EEG in dementia trials
On May 6th, 2025, we will organised the webinar: The role of EEG in dementia trials During this webinar, our speakers Pieter van Mierlo, Dr. Willem de Haan and host Lieza Exalto will explore the following topics:Practical aspects and resti...

